From each FDA label

Do GLP-1s cause diarrhea?

Diarrhea is in the main trial table of 9 labels. The highest rate printed is 30% on Wegovy 2.4 mg (16% on placebo) and the lowest 8.8% on Ozempic 1 mg (1.9% on placebo). Separate trials, so not a ranking. Byetta lists it only among reports after approval, without a rate.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Aug 28, 2026.

Rate against placebo

How often diarrhea happened in each medicine's trials

At the highest dose in each label's main table. Separate trials with different people, so compare each rate with its own placebo group, not with another medicine.

MedicineDoseOn itOn placeboDifferenceLabel
Wegovy2.4 mg30%16%+14 pointsDailyMed
Foundayo17.2 mg25%11%+14 pointsDailyMed
Zepbound15 mg23%8%+15 pointsDailyMed
Saxenda3 mg20.9%9.9%+11.0 pointsDailyMed
Mounjaro15 mg17%9%+8 pointsDailyMed
Trulicity1.5 mg12.6%6.7%+5.9 pointsDailyMed
Victoza1.8 mg12%4%+8 pointsDailyMed
Rybelsus and Ozempic tablets14 mg10%4%+6 pointsDailyMed
Ozempic1 mg8.8%1.9%+6.9 pointsDailyMed
Word for word

What each label says about diarrhea

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • The most common adverse reactions leading to discontinuation were nausea (1.8% versus 0.2%), vomiting (1.2% versus 0%), and diarrhea (0.7% versus 0.1%) for Wegovy and placebo, respectively.
  • In clinical trials in adults for weight reduction, 73% of Wegovy injection-treated patients and 47% of patients receiving placebo reported gastrointestinal adverse reactions, including severe reactions that were reported more frequently among patients receiving Wegovy injection (4.1%) than placebo (0.9%). The most frequently reported reactions were nausea (44% vs. 16%), vomiting (25% vs. 6%), and diarrhea (30% vs. 16%).
  • In the pediatric clinical trial for weight reduction, 62% of Wegovy injection-treated patients and 42% of placebo-treated patients reported gastrointestinal adverse reactions. The most frequently reported reactions were nausea (42% vs. 18%), vomiting (36% vs. 10%), and diarrhea (22% vs. 19%).

Label revised Jun 18, 2026. DailyMed

Ozempic

  • The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation.

Label revised Jun 1, 2026. DailyMed

Zepbound

  • The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time.

Label revised Aug 28, 2026. DailyMed

Mounjaro

  • The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.

Label revised Aug 27, 2026. DailyMed

Foundayo

  • The incidence of nausea, vomiting, and diarrhea was higher during the Foundayo dosage escalation period and decreased over time.

Label revised Jul 29, 2026. DailyMed

Saxenda

  • The most common adverse reactions leading to discontinuation were nausea (2.9% versus 0.2% for Saxenda and placebo, respectively), vomiting (1.7% versus less than 0.1%), and diarrhea (1.4% versus 0%).
  • There have been reports of gastrointestinal adverse reactions, such as nausea, vomiting, and diarrhea, associated with volume depletion and renal impairment.
  • The percentage of patients reporting nausea declined as treatment continued. Other common adverse reactions that occurred at a higher incidence among Saxenda-treated patients included diarrhea, constipation, vomiting, dyspepsia, abdominal pain, dry mouth, gastritis, gastroesophageal reflux disease, flatulence, eructation and abdominal distension.
  • Events of asthenia, fatigue, malaise, dysgeusia and dizziness were mainly reported within the first 12 weeks of treatment with Saxenda and were often co-reported with gastrointestinal events such as nausea, vomiting, and diarrhea.

Label revised Feb 25, 2026. DailyMed

Byetta

  • Adverse reactions reported in ≥1.0% to <2.0% of patients receiving Byetta and reported more frequently than with placebo included decreased appetite, diarrhea, and dizziness.

Label revised Sep 2, 2025. DailyMed

Victoza: listed only among reports after approval, which come with no rate because nobody knows how many people took the medicine. Trulicity: no finding on this in the sections read here.

Not from trials

Reports to FDA about diarrhea

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
OzempicDiarrhea: 6,33170,863
MounjaroDiarrhea: 6,09997,440
TrulicityDiarrhea: 6,06587,279
ZepboundDiarrhea: 4,97380,835
VictozaDiarrhea: 3,03341,462
ByettaDiarrhea: 2,74752,087
WegovyDiarrhea: 1,38025,993
Rybelsus and Ozempic tabletsDiarrhea: 6157,758
SaxendaDiarrhea: 4287,270
FoundayoDiarrhea: 2123,050

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Diarrhea on a GLP-1: common questions

Which GLP-1 causes the most diarrhea?

No trial here ranks them. By the rates each label prints, Wegovy 2.4 mg is highest at 30% (placebo 16%) and Ozempic 1 mg lowest at 8.8% (placebo 1.9%). These come from separate trials with different people and doses, so compare each to its own placebo group.

Does Wegovy cause diarrhea?

In its FDA label, 30% of people taking Wegovy 2.4 mg reported diarrhea, against 16% on placebo.

Does Foundayo cause diarrhea?

In its FDA label, 25% of people taking Foundayo 17.2 mg reported diarrhea, against 11% on placebo.

Does Zepbound cause diarrhea?

In its FDA label, 23% of people taking Zepbound 15 mg reported diarrhea, against 8% on placebo.

Does Saxenda cause diarrhea?

In its FDA label, 20.9% of people taking Saxenda 3 mg reported diarrhea, against 9.9% on placebo.

Does Mounjaro cause diarrhea?

In its FDA label, 17% of people taking Mounjaro 15 mg reported diarrhea, against 9% on placebo.

Does Trulicity cause diarrhea?

In its FDA label, 12.6% of people taking Trulicity 1.5 mg reported diarrhea, against 6.7% on placebo.

How long does diarrhea last on a GLP-1?

Labels describe when it happens, not how many days it lasts. Ozempic: "The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation." Rybelsus and Ozempic tablets: "The majority of reports of nausea, vomiting and/or diarrhea occurred during dose escalation." Zepbound: "The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time."

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.